Mirum Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.45 | -$0.39 | -$0.42 |
| Q2 2024 | 2 | -$0.51 | -$0.44 | -$0.47 |
| Q3 2024 | 2 | -$0.48 | -$0.42 | -$0.45 |
| Q4 2024 | 7 | -$0.39 | -$0.24 | -$0.30 |
| Q1 2025 | 4 | -$0.52 | -$0.09 | -$0.30 |
| Q2 2025 | 2 | -$0.25 | -$0.21 | -$0.23 |
| Q3 2025 | 2 | -$0.16 | -$0.14 | -$0.15 |
| Q4 2025 | 2 | -$0.08 | -$0.07 | -$0.07 |
Mirum Pharmaceuticals, Inc. Earnings Date And Information
Mirum Pharmaceuticals, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-0.3 earnings per share for the quarter, topping analysts' consensus estimates of $-0.45 by $0.15. The company had revenue of 90.38 M for the quarter and had revenue of 186.37 M for the year. Mirum Pharmaceuticals, Inc. has generated $-4 earnings per share over the last year ($-4 diluted earnings per share) and currently has a price-to-earnings ratio of -21.97. Mirum Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Mirum Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$0.45 | -$0.30 | 0.15 | $81.99 M | $90.38 M |
| 08/07/2024 | Q2 2024 | -$0.48 | -$0.52 | -0.04 | $75.03 M | $77.88 M |
| 05/08/2024 | Q1 2024 | -$0.40 | -$0.54 | -0.14 | $69.22 M | |
| 03/15/2024 | Q4 2023 | -$0.71 | $69.55 M | |||
| 11/02/2023 | Q3 2023 | -$0.64 | -$0.57 | 0.07 | $38.60 M | $47.73 M |
| 08/07/2023 | Q2 2023 | -$1.94 | $30.44 M | $37.50 M | ||
| 05/04/2023 | Q1 2023 | -$0.96 | -$0.80 | 0.16 | $31.60 M | |
| 03/08/2023 | Q4 2022 | -$0.98 | -$0.99 | -0.01 | $27.91 M | |
| 11/09/2022 | Q3 2022 | -$1.05 | -$1.02 | 0.03 | $20.81 M | $18.78 M |
| 08/04/2022 | Q2 2022 | -$1.05 | -$0.84 | 0.21 | $15.42 M | $17.48 M |
| 05/05/2022 | Q1 2022 | -$1.39 | -$1.17 | 0.22 | $12.89 M | |
| 03/09/2022 | Q4 2021 | -$0.61 | $1.88 | 2.49 | $3.14 M | |
| 11/15/2021 | Q3 2021 | -$1.63 | -$1.55 | 0.08 | $1.00 M | $5.00 M |
| 08/05/2021 | Q2 2021 | -$0.41 | -$1.45 | -1.04 | $17.40 M | $11.00 M |
| 05/06/2021 | Q1 2021 | -$0.67 | -$1.68 | -1.01 | $0 | |
| 03/09/2021 | Q4 2020 | -$0.57 | -$1.43 | -0.86 | $0 | |
| 11/12/2020 | Q3 2020 | -$0.99 | -$0.86 | 0.13 | $0 | |
| 08/06/2020 | Q2 2020 | -$0.88 | -$0.93 | -0.05 | $0 | |
| 05/07/2020 | Q1 2020 | -$0.81 | -$0.86 | -0.05 | $0 | |
| 03/12/2020 | Q4 2019 | -$0.85 | -$0.79 | 0.06 | $0 |
Mirum Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Mirum Pharmaceuticals, Inc.'s earnings date?
Mirum Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
Did Mirum Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Mirum Pharmaceuticals, Inc. (:MIRM) reported $-0.3 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.45 by $0.15.
-
How can I listen to Mirum Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Mirum Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Mirum Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Mirum Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Mirum Pharmaceuticals, Inc. generate each year?
Mirum Pharmaceuticals, Inc. (:MIRM) has a recorded annual revenue of $186.37 M.
-
How much profit does Mirum Pharmaceuticals, Inc. generate each year?
Mirum Pharmaceuticals, Inc. (:MIRM) has a recorded net income of $186.37 M. Mirum Pharmaceuticals, Inc. has generated $-4 earnings per share over the last four quarters.
-
What is Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio?
Mirum Pharmaceuticals, Inc. (:MIRM) has a price-to-earnings ratio of -21.97 and price/earnings-to-growth ratio is -1.9.
